154 related articles for article (PubMed ID: 23641042)
1. Re: Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels and Re: Inequalities in human papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination.
Harper DM; Groner JA; Griffith RS; Harper WH
J Natl Cancer Inst; 2013 May; 105(10):749-50. PubMed ID: 23641042
[No Abstract] [Full Text] [Related]
2. Inequalities in Human Papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination.
Brisson M; Drolet M; Malagón T
J Natl Cancer Inst; 2013 Feb; 105(3):158-61. PubMed ID: 23297040
[No Abstract] [Full Text] [Related]
3. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
[TBL] [Abstract][Full Text] [Related]
4. Response.
Boily MC; Brisson M; Drolet M; Malagón T
J Natl Cancer Inst; 2013 May; 105(10):750-1. PubMed ID: 23814885
[No Abstract] [Full Text] [Related]
5. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China.
Duan R; Qiao Y; Clifford G; Zhao F
Cancer Med; 2020 Jan; 9(1):374-384. PubMed ID: 31714036
[TBL] [Abstract][Full Text] [Related]
6. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
7. [To the Editors: HPV vaccination].
Katona G
Orv Hetil; 2013 Jul; 154(30):1197. PubMed ID: 23876618
[No Abstract] [Full Text] [Related]
8. [Prevention of papillomavirus-associated cancer].
Signorelli C
Ann Ig; 2008; 20(3 Suppl 1):65-74. PubMed ID: 18773608
[TBL] [Abstract][Full Text] [Related]
9. [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].
Acs N; Bata Z; Danko D; Hernádi Z; Kálmán M; Kornya L; Kovács J; Mézáros G; Molnár MP; Mór Z; Novák Z; Sobel G; Szentirmay Z; Takács L; Tisza T
Orv Hetil; 2012 Dec; 153 Suppl():3-38. PubMed ID: 23687666
[No Abstract] [Full Text] [Related]
10. Excess Cancer Cases and Medical Costs Due to Suboptimal Human Papillomavirus Vaccination Coverage in California.
Baughan EB; Keizur EM; Damico CA; Arnold EM; Ko JS; Klausner JD
Sex Transm Dis; 2019 Aug; 46(8):527-531. PubMed ID: 31295221
[TBL] [Abstract][Full Text] [Related]
11. Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.
Drolet M; Deeks SL; Kliewer E; Musto G; Lambert P; Brisson M
Vaccine; 2016 Apr; 34(16):1874-80. PubMed ID: 26954465
[TBL] [Abstract][Full Text] [Related]
12. Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.
Lehtinen M; Baussano I; Paavonen J; Vänskä S; Dillner J
Expert Rev Vaccines; 2019 Feb; 18(2):153-160. PubMed ID: 30657348
[TBL] [Abstract][Full Text] [Related]
13. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
14. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
16. Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.
Burger EA; Lee K; Saraiya M; Thompson TD; Chesson HW; Markowitz LE; Kim JJ
Cancer; 2016 Jul; 122(13):2057-66. PubMed ID: 27124396
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
18. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention.
Awolude OA; Morhason-Bello IO; Denny LA; Adewole IF
Vaccine; 2013 Dec; 31 Suppl 5():vii-x. PubMed ID: 24331751
[No Abstract] [Full Text] [Related]
20. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods.
Watson M; Saraiya M; Ahmed F; Cardinez CJ; Reichman ME; Weir HK; Richards TB
Cancer; 2008 Nov; 113(10 Suppl):2841-54. PubMed ID: 18980203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
